Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease melanoma, malignant
Comorbidity C0220650|brain metastases
Sentences 53
PubMedID- 23634283 brain metastases occur in 15% of patients with melanoma and are associated with a dismal prognosis.
PubMedID- 24112545 Whole brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial.
PubMedID- 26500646 Several studies have also provided evidence of ipilimumab effectiveness in cases of melanoma with brain metastases (165, 166).
PubMedID- 21205554 Median survival for melanoma with brain metastases is even lower i.e.
PubMedID- 25768829 Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without braf mutation and treatment.
PubMedID- 25991583 Treatment patterns and outcomes in braf v600e-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
PubMedID- 24292400 Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the anatolian society of medical oncology.
PubMedID- 20960525 Prognostic factors for survival in melanoma patients with brain metastases.
PubMedID- 23170278 Ipilimumab in a phase ii trial of melanoma patients with brain metastases.
PubMedID- 21074062 Temozolomide and fotemustine are preferentially used in melanoma patients with brain metastases in the united states and in europe, respectively, with modest clinical activity.
PubMedID- 22906295 Complete skin, mucosal and retinal examination failed to show any primary lesion, therefore a diagnosis of primary cervical melanoma with brain metastases was made.
PubMedID- 23845462 The development of brain metastases is common in patients with metastatic melanoma and heralds a particularly poor prognosis.
PubMedID- 26205399 Clinical trials in melanoma patients with brain metastases.
PubMedID- 25859247 Nevertheless, the activity of ipilimumab in 72 melanoma patients with brain metastases was assayed in an open-label, phase ii trial (41).
PubMedID- 22051508 Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
PubMedID- 24403263 We analyzed the clinical and radiographic records of melanoma patients with brain metastases who were treated with whole brain radiation therapy or stereotactic radiosurgery between 2005 and 2012.
PubMedID- 23462208 The purpose of this study was to investigate the efficacy of ctla-4 inhibitors in the treatment of metastatic melanoma with limited brain metastases treated with stereotactic radiosurgery (srs).
PubMedID- 25164960 Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.
PubMedID- 26511495 Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
PubMedID- 24250878 Hemorrhagic brain metastases as a manifestation of metastatic malignant melanoma.
PubMedID- 20169105 Other clinical trials using continuous gm-csf administration in advanced prostate cancer [42] or sustained g-csf in stage iv melanoma with brain metastases [43] reported a much better survival than when approved therapies were used.
PubMedID- 22488042 Other recent series at institutions that pursue similar treatment schemas have demonstrated similar outcomes, both in the setting of melanoma patients with brain metastases [36] and in melanoma patients with limited systemic metastases amenable to complete surgical resection [37].
PubMedID- 22453023 We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of braf inhibitors.
PubMedID- 22084751 Gamma knife radiosurgery or surgical resection of cns disease prior to chemotherapy improves survival versus delayed treatment in patients melanoma with melanoma brain metastases [4].
PubMedID- 25241016 Results: this article presents the results of bibliographic search, the conclusions of the literature and the recommendations concerning locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma.
PubMedID- 24954062 Background: brain metastases are common in patients with melanoma, and optimal management is not well defined.
PubMedID- 25275060 Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery.
PubMedID- 22220282 It is therefore likely that improved survival can currently be achieved in at least a subset of melanoma patients with brain metastases.
PubMedID- 22456429 Background: brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease.
PubMedID- 23504304 Malignant melanoma with brain metastases remains a difficult disease to treat.
PubMedID- 22385786 Therapeutic braf inhibitors have shown clinically meaningful activity, particularly in metastatic braf v600e mutated melanoma including patients with brain metastases.
PubMedID- 23621583 In addition, the results of the phase ii study of dabrafenib in melanoma patients with active brain metastases (break-mb) and the phase i/ii study of dabrafenib/trametinib are examined.
PubMedID- 22584956 Venous thromboembolism (vte) is a frequent complication in melanoma patients with brain metastases (bm).
PubMedID- 23579338 The purpose of this pilot analysis was to find the effectiveness of vemurafenib, an oral braf inhibitor, and radiation therapy in v600 mutated melanoma with brain metastases.
PubMedID- 24795353 A melanoma patient with brain metastases was treated by gamma-knife radiosurgery and immunotherapy with autologous tumor-lysate-loaded dendritic cells (dc).
PubMedID- 24077406 Background: the development of brain metastases is common in patients with melanoma and is associated with a poor prognosis.
PubMedID- 24377476 Background: brain metastases commonly occur in patients with metastatic melanoma and are associated with a poor prognosis.
PubMedID- 22094106 Background: brain metastases afflict approximately half of patients with metastatic melanoma (mm) and small cell lung cancer (sclc) and represent the direct cause of death in 60 to 70% of those affected.
PubMedID- 23051966 Background: brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17-22 weeks.
PubMedID- 25057167 Background: both gamma-knife radiosurgery (gkrs) and braf inhibitors (braf-i) have been shown to be useful in melanoma patients with brain metastases (bms), thus suggesting that it could be interesting to combine their respective advantages.
PubMedID- 23788878 A number of clinical trials showed low efficacy of anti-cancer agents in melanoma patients with brain metastases.
PubMedID- 25864098 Survival patterns following brain metastases for patients with melanoma in the map-kinase inhibitor era.
PubMedID- 24455677 Therapies that affect the neoangiogenesis axis are not currently recommended in melanoma patients with brain metastases but data from ongoing trials are awaited with interest [27].
PubMedID- 23196331 The balance of risk of bleeding and thrombosis in melanoma patients with brain metastases.
PubMedID- 23687494 Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.
PubMedID- 23108247 Recent findings: braf inhibitors and the immunomodulatory anticytotoxic t-lymphocyte-associated antigen 4 antibody ipilimumab have shown clinically meaningful activity in melanoma patients with brain metastases.
PubMedID- 23117880 Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma.
PubMedID- 22904648 However, retrospective subgroup analysis of 12 melanoma subjects with treated brain metastases who received ipilimumab showed that two achieved a partial response and an additional three had stable disease.36 median overall survival in this small group was 14 months and ranged to greater than 56 months.
PubMedID- 26565903 Expression of activated akt1 resulted in highly metastatic melanomas with lung and brain metastases in 67% and 17% of our mice, respectively.
PubMedID- 23271367 Though brain metastases, especially with lung cancer, melanoma and breast cancer, are becoming a common clinical problem, limited treatment options have existed [23], such as gamma knife radiosurgeries [24,25], stereotactic radiosurgery [26] or irradiation [27], uvc irradiation [28] and whole brain radiotherapy [29–31].

Page: 1 2